Hungarian laboratory scientist András Pál Bózsik, whose name is inseparable from the Revolutionary advances in Lyme disease diagnostics. In creating the DualDur test, he has created a solution that has revolutionised the way Lyme disease is detected. But what makes András Pál Bózsik's work so special?
Who is András Pál Bózsik?
András Pál Bózsik on Lyme Diagnostics Ltd. the head of the Lyme Borreliosis Foundation member of the Board of Trustees. Her professional background is complex and wide-ranging: her work focuses on the innovative Lyme disease diagnostics in particular, to the development of the DualDur direct detection test to develop.
His work was greatly inspired by his father, Dr. Béla Bózsik, who worked as a serological expert and was involved in the description of the first cases of Lyme disease in Hungary in 1985. This family knowledge and tradition formed the basis for András Pál Bózsik to take Lyme disease detection to a new level of diagnostics.
Professional Background and Roots
The Paternal Inheritance
Father of András Pál Bózsik, Dr. Béla Bózsik, working in the central laboratory of the National Institute of Public Health, developed Hungary's first serological tests for Lyme disease. Dr Béla Bózsik used the similarity with the syphilis pathogen to create the diagnostic basis on which his son later built the DualDur test.
András Paul Bózsik's Own Way
András Pál Bózsik has been in contact with hundreds of doctors at conferences and training courses both at home and abroad. He has been an active participant in Central Europe's largest clinical study on Lyme disease, which gave him the opportunity to see directly the diagnostic difficulties and the need to solve them.
The DualDur Test: Innovation
What is DualDur?
A Dual major an direct Lyme disease diagnostic test, developed by Lyme Diagnostics Ltd. This is not just another test - it is a paradigm shift in Lyme disease diagnostics.
Operating Principle
The traditional serological (indirect) tests measure the immune response - whether the body has responded to the infection by producing antibodies. A DualDur, however, takes a significantly different approach:
- Not the immune response but the pathogen itself
- A Borrelia bacteria shows up directly in the blood
- The blood sample is taken from about to a hundredfold concentration focus on
- Identification of the pathogen based on artificial intelligence is done by an image recognition algorithm
Benefits of the Technology
The use of artificial intelligence in the DualDur test has several advantages:
- Eliminating human error - the AI algorithm is objective and consistent
- Statistical evaluation - the amount of the pathogen can be determined in the sample
- Possibility of specific antibodies - Presence can be detected with antibodies against Borrelia
- Objective diagnostics - not dependent on the subjective observation of the laboratory technician
Clinical Performance and Outcomes
The results of clinical trials of the DualDur test show excellent efficacy:
- Positive predictive value: 96% - can detect infection in 96% of presumptive patients
- Early detection - can give positive results as early as 4-6 days after infection
- Therapeutic control - the effectiveness of the treatment can be demonstrated by comparing the results before and after treatment
This last point is particularly important because it allows doctors to monitor the success of treatment - not just the presence of infection.
Availability of the DualDur Test
Global Presence
By 2025, the DualDur test taken in 32 countries, including in places as far afield as Australia and Turkey. This number continues to grow as the medical community recognises the value and accuracy of the test.
Regular sending of samples
Regularly about ten countries send samples weekly frequency, indicating that the DualDur test is an accepted and reliable solution in international practice.
Lyme Diagnostics Ltd. - The Company
A Lyme Diagnostics Ltd. developer and operator of the DualDur test. Under the leadership of András Pál Bózsik, the company has become an international leader in Lyme disease diagnostics.
Scientific and Public Activity
András Pál Bózsik's professional activity goes beyond the development of the test:
- Lyme Borreliosis Foundation member of the Board of Trustees
- Regular author of the Health Guide portal
- Participant in the largest clinical Lyme study in Central Europe
- To the father of a fellow author, To Dr. Béla Bózsik, who published in the The Lancet and other professional journals on Lyme disease case numbers in Hungary
Patent Innovation
Patent solutions related to the DualDur test have also been recognised internationally. Pharmaonline reported on the recent patents that have been granted to AI-based Lyme disease detection method apply.
Summary
András Pál Bózsik is a representative of the Hungarian scientific community who not only accumulates theoretical knowledge, but also transforms it into concrete, life-saving solutions. He has revolutionised the diagnosis of Lyme disease with the development of the DualDur test, and his work is internationally recognised.
Throughout his career, he has proven that Hungarian research and development is capable of world-class results. The name of András Pál Bózsik will in future be As an innovative thinker in Lyme disease diagnostics remains in our memory.
Read more
Are you more deeply interested in this topic?
DualDur - the role of direct diagnostics in Lyme disease detection
Hungarian 
English 
Polish 
Spanish